A vaccine for dengue fever, known as Dengvaxia (CYD-TDV), has been approved in some countries for use in individuals aged 9-45 years who have had at least one prior dengue infection. Its use in children should be carefully considered by healthcare providers, as it is not recommended for those who have not previously been infected with the dengue virus.
